SCHEMBL15320022

SCHEMBL15320022

CCC1=CC(=O)CN(C(=O)OC(C)(C)C)[C@@H]1CO[Si](C)(C)C(C)(C)C

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.37
MEN1 O00255 3/20 0.37
ALDH1A1 P00352 5/20 0.35
L3MBTL1 Q9Y468 1/20 0.33
ATM Q13315 2/20 0.32
FKBP1A P62942 1/20 0.32
TOP2A P11388 1/20 0.32
HSD11B1 P28845 1/20 0.32
NR1H2 P55055 1/20 0.32
TSHR P16473 3/20 0.32
GLA P06280 2/20 0.32
LMNA P02545 2/20 0.32
TP53 P04637 1/20 0.32
PTPN1 P18031 1/20 0.32
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
HPGD P15428 1/20 0.32
HSD17B10 Q99714 1/20 0.32
AR P10275 1/20 0.31
KLK7 P49862 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15320018 1.00 KMT2A (0.37) KMT2AMEN1ALDH1A1L3MBTL1ATM
SCHEMBL15319869 0.90 KMT2A (0.36) KMT2AMEN1ALDH1A1L3MBTL1ATM
SCHEMBL15319871 0.90 KMT2A (0.36) KMT2AMEN1ALDH1A1L3MBTL1ATM
SCHEMBL15319966 0.86 KMT2A (0.38) KMT2AMEN1ALDH1A1L3MBTL1ATM
SCHEMBL15319968 0.86 KMT2A (0.38) KMT2AMEN1ALDH1A1L3MBTL1ATM
SCHEMBL15319563 0.83 KMT2A (0.36) KMT2AMEN1ALDH1A1L3MBTL1ATM
SCHEMBL15318882 0.83 KMT2A (0.36) KMT2AMEN1ALDH1A1L3MBTL1ATM
SCHEMBL15318883 0.83 KMT2A (0.36) KMT2AMEN1ALDH1A1L3MBTL1ATM
SCHEMBL15319566 0.83 KMT2A (0.36) KMT2AMEN1ALDH1A1L3MBTL1ATM
SCHEMBL16559037 0.83 MEN1 (0.36) KMT2AMEN1ALDH1A1L3MBTL1ATM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2834239-B1 HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS ENTASIS THERAPEUTICS LTD (GB) 2017-12-27 EP disclosed
US-9623014-B2 β-lactamase inhibitor compounds ENTASIS THERAPEUTICS LIMITED (GB) 2017-04-18 US disclosed
US-20160175290-A1 BETA-LACTAMASE INHIBITOR COMPOUNDS ASTRAZENECA PHARMACEUTICALS LP 2016-06-23 US disclosed
US-9309245-B2 Beta-lactamase inhibitor compounds ENTASIS THERAPEUTICS LIMITED (GB) 2016-04-12 US disclosed
US-20150073011-A1 Beta-Lactamase Inhibitor Compounds ASTRAZENECA AB (SE) 2015-03-12 US disclosed
EP-2834239-A1 HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS Astrazeneca AB (SE) 2015-02-11 EP disclosed
WO-2013150296-A1 HETEROBICYCLIC COMPOUNDS AS BETA-LACTAMASE INHIBITORS ASTRAZENECA AB (SE) 2013-10-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160175290-A1 BETA-LACTAMASE INHIBITOR COMPOUNDS LCT, MGAM, SI KMT2A 1304/4885MEN1 3098/4885ALDH1A1 319/4885
US-20150073011-A1 Beta-Lactamase Inhibitor Compounds LCT, MGAM, SI KMT2A 1304/4885MEN1 3098/4885ALDH1A1 319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.